Kiyoko Uno-Eder
Teikyo Academic Research Center, JapanTitle: Challenges with PCSK9 inhibitors Use in Asia Given Real-World Data Implications
Abstract
Number of Clinical trials have showed the powerful LDL-C lowering and cardiovascular event reduction effects of PCSK9 inhibitors. As a result, lipid management guidelines in many countries implemented PCSK9 inhibitors for LDL-C control in high-risk patients who required additional LDL-C reduction. While “the lower, the better” approach to LDL-C seems straightforward, the relatively high cost of the PCSK9 inhibitors complicates the real-world prescription and distribution of these interventions. PCSK9 inhibitors show efficacious, safe, and well-tolerated intervention in real-world studies; however, the discontinuation rate has been high, at over 30%, and the most common reason for discontinuation has been high treatment costs. An international panel, including patients, pointed out uncertainty in the evidence concerning availability and cost. Given the current state, driven to some degree by “ability and willingness to pay” for PCSK9 inhibitors, this presentation will explore what might be done to deliver this useful but resource intense drug to patients in need appropriately.
Biography
Kiyoko Uno-Eder trained as an MD, with a focus in cardiologist as well as earning her PhD at the University of Tsukuba, Japan. She accepted a postdoctoral fellowship at Cleveland Clinic, US from 2009 to 2012. From 2014, she joined Sanofi Japan to lead the cardiovascular medical team. From 2019, she serves as an associate professor leading the Teikyo University Academic Research Center for medical research along with ongoing clinical work.
Organization Location
1309 Coffeen Avenue, STE 1200, Sheridan, Wyoming 82801, USA
Mail us at
Program Enquiry
cardiacare@scientexconferences.com
General Enquiry
contact@scientexconferences.com
Registration Enquiry
finance@scientexconferences.com
cardiacare@scientexevents.org
Our Social Presence
Call us at
USA : (+1) 914 520 5013